Fibrinogen gene haplotypes in relation to risk of coronary events and coronary and extracoronary atherosclerosis: The Rotterdam Study

Summary

Fibrin network structure has been correlated with coronary disease. Fibrinogen γ and α (FGG and FGA) gene haplotypes (chromosome 4q28) may be associated with fibrin network structure, and thereby with rigidity of the fibrin clot and sensitivity of the fibrin clot to the fibrinolytic system. Through these mechanisms they may influence risk of cardiovascular disease. We set out to investigate the relation between combined fibrinogen FGG and FGA gene haplotypes, representing the common variation of the fibrinogen FGG and FGA genes, coronary events and measures of coronary and extracoronary atherosclerosis. The study was embedded in the Rotterdam Study, a prospective populationbased study among men and women aged ≥ 55 years. Common haplotypes were studied using seven tagging SNPs across a 30-kb region with the FGG and FGA genes. Incident coronary events were registered, and carotid intima-media thickness, carotid plaques, ankle-arm index, aortic calcification and coronary calcification were assessed. Seven haplotypes with frequencies >1% covered 97.5% of the genetic variation. In 5,667 participants without history of coronary heart disease (CHD), 733 CHD cases occurred during a median follow-up time of 11.9 years. Fibrinogen gene haplotypes were not associated with coronary events. Fibrinogen gene haplotypes did not show a consistent association with measures of coronary and extracoronary atherosclerosis. In conclusion, fibrinogen FGG and FGA gene haplotypes are not associated with coronary events, coronary atherosclerosis or extracoronary atherosclerosis. Confirmation of these findings by future population-based studies is warranted.

Keywords

Coronary disease - atherosclerosis - epidemiology - genetics - fibrinogen

• References

• 1 Herrick S, Blanc-Brude O, Gray A. et al Fibrinogen. Int J Biochem Cell Biol 1999; 31: 741-746.
• 2 Danesh J, Lewington S, Thompson SG. et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. J Am Med Assoc 2005; 294: 1799-1809.
• 3 Koenig W. Fibrin(ogen) in cardiovascular disease: an update. Thromb Haemost 2003; 89: 601-609.
• 4 Fatah K, Hamsten A, Blomback B. et al Fibrin gel network characteristics and coronary heart disease: relations to plasma fibrinogen concentration, acute phase protein, serum lipoproteins and coronary atherosclerosis. Thromb Haemost 1992; 68: 130-135.
• 5 Fatah K, Silveira A, Tornvall P. et al. Proneness to formation of tight and rigid fibrin gel structures in men with myocardial infarction at a young age. Thromb Haemost 1996; 76: 535-540.
• 6 Collet JP, Park D, Lesty C. et al. Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed: dynamic and structural approaches by confocal microscopy. Arterioscler Thromb Vasc Biol 2000; 20: 1354-1361.
• 7 Dunn EJ, Ariens RA, de Lange M. et al. Genetics of fibrin clot structure: a twin study. Blood 2004; 103: 1735-1740.
• 8 Mills JD, Ariens RA, Mansfield MW. et al. Altered fibrin clot structure in the healthy relatives of patients with premature coronary artery disease. Circulation 2002; 106: 1938-1942.
• 9 de Maat MP, Verschuur M. Fibrinogen heterogeneity: inherited and noninherited. Curr Opin Hematol 2005; 12: 377-383.
• 10 Curran JM, Fatah-Ardalani K, Tornvall P. et al. A hypothesis to explain the reported association of the alpha-fibrinogen A312 allele with thromboembolic disease. Thromb Haemost 2001; 85: 1122-1123.
• 11 Standeven KF, Grant PJ, Carter AM. et al. Functional analysis of the fibrinogen Aalpha Thr312Ala polymorphism: effects on fibrin structure and function. Circulation 2003; 107: 2326-2330.
• 12 Carter AM, Catto AJ, Grant PJ. Association of the alpha-fibrinogen Thr312Ala polymorphism with poststroke mortality in subjects with atrial fibrillation. Circulation 1999; 99: 2423-2426.
• 13 Carter AM, Catto AJ, Kohler HP. et al. alpha-fibrinogen Thr312Ala polymorphism and venous thromboembolism. Blood 2000; 96: 1177-1179.
• 14 Uitte de Willige S, de Visser MC, Houwing-Duistermaat JJ. et al. Genetic variation in the fibrinogen gamma gene increases the risk of deep venous thrombosis by reducing plasma fibrinogen γ levels. Blood 2005; 106: 4176-4183.
• 15 Mannila MN, Eriksson P, Lundman P. et al. Contribution of haplotypes across the fibrinogen gene cluster to variation in risk of myocardial infarction. Thromb Haemost 2005; 93: 570-577.
• 16 Mannila MN, Eriksson P, Ericsson CG. et al. Epistatic and pleiotropic effects of polymorphisms in the fibrinogen and coagulation factor XIII genes on plasma fibrinogen concentration, fibrin gel structure and risk of myocardial infarction. Thromb Haemost 2006; 95: 420-427.
• 17 Hofman A, Grobbee DE, de Jong PT. et al. Determinants of disease and disability in the elderly: the Rotterdam Elderly Study. Eur J Epidemiol 1991; 7: 403-422.
• 18 Kardys I, Kors JA, van der Meer IM. et al. Spatial QRS-T angle predicts cardiac death in a general population. Eur Heart J 2003; 24: 1357-1364.
• 19 Nickerson D. Seattle SNPs: NHLBI Program for Genomic Applications, UW-FHCRC, Seattle, WA, USA http://pga.gs.washington.edu Last accessed November 22, 2006.
• 20 Epstein MP, Satten GA. Inference on haplotype effects in case-control studies using unphased genotype data. Am J Hum Genet 2003; 73: 1316-1329.
• 21 Lake SL, Lyon H, Tantisira K. et al. Estimation and tests of haplotype-environment interaction when linkage phase is ambiguous. Hum Hered 2003; 55: 56-65.
• 22 van der Meer IM, Bots ML, Hofman A. et al. Predictive value of noninvasive measures of atherosclerosis for incident myocardial infarction: the Rotterdam Study. Circulation 2004; 109: 1089-1094.
• 23 Vliegenthart R, Oudkerk M, Hofman A. et al. Coronary calcification improves cardiovascular risk prediction in the elderly. Circulation 2005; 112: 572-577.
• 24 Agatston AS, Janowitz WR, Hildner FJ. et al. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990; 15: 827-832.
• 25 WHO. International statistical classification of diseases and related health problems, 10th revision. Geneva; Switzerland: 1992
• 26 Schaid DJ, Rowland CM, Tines DE. et al. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002; 70: 425-434.
• 27 Ajjan RA, Grant PJ. Role of clotting factors and fibrin structure in predisposition to atherothrombotic disease. Expert Rev Cardiovasc Ther 2005; 3: 1047-1059.
• 28 Nair CH, Ali M, Tseytlina E. et al. Fibrinogen and fibrin cell characteristics as risk factors in vascular disease: role of lipids. Thromb Haemost 1993; 69: 807.
• 29 Jorneskog G, Egberg N, Fagrell B. et al. Altered properties of the fibrin gel structure in patients with IDDM. Diabetologia 1996; 39: 1519-1523.
• 30 Behague I, Poirier O, Nicaud V. et al. Beta fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction. The ECTIM Study. Etude Cas- Temoins sur l'Infarctus du Myocarde. Circulation 1996; 93: 440-449.
• 31 de Maat MP, Kastelein JJ, Jukema JW. et al. –455G/A polymorphism of the beta-fibrinogen gene is associated with the progression of coronary atherosclerosis in symptomatic men: proposed role for an acutephase reaction pattern of fibrinogen. REGRESS group. Arterioscler Thromb Vasc Biol 1998; 18: 265-271.
• 32 Boekholdt SM, Bijsterveld NR, Moons AH. et al. Genetic variation in coagulation and fibrinolytic proteins and their relation with acute myocardial infarction: a systematic review. Circulation 2001; 104: 3063-3068.
• 33 Uitte de Willige S, Doggen CJ, de Visser MC. et al. Haplotypes of the fibrinogen gamma gene do not affect the risk of myocardial infarction. J Thromb Haemost 2006; 4: 474-476.